Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Curr Pharm Des. 2009;15(33):3853-60. doi: 10.2174/138161209789649376.
The heterodimeric transcription factor HIF-1 (hypoxia-inducible factor-1) induces angiogenesis, a process that is aberrantly elevated in cancer. The HIF-1beta subunit is constitutively expressed, but the levels of the HIF-1alpha subunit are robustly regulated, increasing under hypoxic conditions and decreasing in normoxia. These changes result from rapid alterations in the rates of HIF-1alpha production and degradation. While the regulation of HIF-1alpha degradation is understood in significant detail, much less is known about the regulation of HIF-1alpha biosynthesis. Here, we review recent evidence that HIF-1alpha production is effectively controlled by post-transcriptional mechanisms. We focus on the RNA-binding proteins (RBPs) and the non-coding RNAs that interact with the HIF-1alpha mRNA and influence its half-life and translation rate. HIF-1alpha mRNA-binding factors are emerging as promising pharmacological targets to control HIF-1alpha production selectively and efficiently.
异源二聚体转录因子 HIF-1(缺氧诱导因子-1)诱导血管生成,这是癌症中异常升高的过程。HIF-1β亚基持续表达,但 HIF-1α亚基的水平受到严格调节,在缺氧条件下增加,在常氧条件下减少。这些变化是由于 HIF-1α产生和降解速率的快速变化所致。虽然 HIF-1α降解的调节已被详细阐明,但 HIF-1α生物合成的调节却知之甚少。在这里,我们回顾了最近的证据,表明 HIF-1α的产生受到转录后机制的有效控制。我们专注于与 HIF-1α mRNA 相互作用并影响其半衰期和翻译率的 RNA 结合蛋白 (RBP) 和非编码 RNA。HIF-1α mRNA 结合因子作为有前途的药理学靶点,可选择性和有效地控制 HIF-1α 的产生。